William Blair Weighs in on CRISPR Therapeutics AG’s Q3 2024 Earnings (NASDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) – William Blair lifted their Q3 2024 earnings estimates for CRISPR Therapeutics in a note issued to investors on Tuesday, August 6th. William Blair analyst S. Corwin now forecasts that the company will post earnings per share of ($1.18) for the quarter, up from their prior estimate of ($1.26). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.52) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.63) EPS, FY2024 earnings at ($4.68) EPS, Q1 2025 earnings at ($1.29) EPS, Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.92) EPS and FY2025 earnings at ($4.42) EPS.

Several other equities analysts have also commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Chardan Capital cut their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday. Citigroup dropped their price target on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, May 23rd. Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Finally, Needham & Company LLC dropped their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $74.00.

CRISPR Therapeutics Trading Down 1.8 %

CRSP stock traded down $0.85 during trading on Thursday, reaching $47.01. The stock had a trading volume of 998,709 shares, compared to its average volume of 1,596,176. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The company has a market capitalization of $3.99 billion, a P/E ratio of -17.28 and a beta of 1.70. The firm has a fifty day moving average price of $56.72 and a 200 day moving average price of $62.88.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.98) EPS.

Insider Activity

In related news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the sale, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CRSP. Riggs Asset Managment Co. Inc. boosted its holdings in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the period. SFE Investment Counsel boosted its stake in shares of CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after purchasing an additional 203 shares in the last quarter. Orion Capital Management LLC raised its stake in CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after buying an additional 220 shares in the last quarter. National Bank of Canada FI lifted its stake in shares of CRISPR Therapeutics by 35.0% during the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after purchasing an additional 220 shares during the last quarter. Finally, Larson Financial Group LLC grew its stake in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.